Dialog Box

ACTICCA for Biliary Tract Cancer

Trial Name: ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma (ACTRN12615001283561).


Patients Involved: Patients with histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection.

Treatment Given: Adjuvant chemotherapy with gemcitabine and cisplatin compared vs. capecitabine.

Rationale for Treatment: It is hoped that the findings of this study will provide details on whether giving cisplatin and gemcitabine chemotherapy following surgery for cancer of the biliary tract is a safe and effective treatment to reduce the chance of disease progression and increase survival time and quality of life.

Recruitment: The trial opened in July 2016. The aim is to recruit 50 patients from 15 Australian sites.

Sites Involved: 6 from various states in Australia, with several more to open over the coming year. 

For further information please go to:


Any trial correspondence should be directed to the ACTICCA Trial Coordinator via email acticca1@ctc.usyd.edu.au.